EMEA and gene therapy medicinal products development in the European union

Journal of Biomedicine and Biotechnology

Volumn 2003, Issue 1, 2003, Pages 3-8

  Amati, Marisan Papaluca ^a   Pignatti, Francesco ^a   Nolte, Alexis ^a   Amerasinghe, Nirosha ^a   Gustafsson, Daniel ^a   Moulon, Isabelle ^a   Le Courtois, Patrick ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; ORPHAN DRUG;

AUTHORITY; CLINICAL RESEARCH; COMPETENCE; DRUG DESIGN; DRUG EFFICACY; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; EUROPEAN MEDICINE EVALUATION AGENCY; EUROPEAN UNION; EVALUATION; GENE THERAPY; GOOD CLINICAL PRACTICE; HEALTH PROMOTION; HUMAN; MEDICAL SOCIETY; REGULATORY MECHANISM; RESPONSIBILITY; REVIEW;

EID: 0037671818     PISSN: 11107243     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1110724303209104     Document Type: Review

References (14)

1. Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal-Products. Official Journal of the European Communities. 1993;(L 214):1-21.
2. Sauer F. Europe and medicines: role of the EMEA. Ann Pharm Fr. 2000;58(4):278-285.
3. Healy EM Katin KI. The European Agency for the Evaluation of Medicinal Product's centralized approach to product approval: current status Drug In J. 1999;33(4):969-978.
4. European Agency for the Evaluation of Medicinal Products. Seventh Annual Report 2001. Available at: http://www.emea.eu.int/pdfs/general/direct/emeaar/005201en.pdf, accessed July 10, 2002.
5. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities. 2001;(L 18):1-5.
6. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official Journal of the European Communities. 2001;(L 311):67-128.
7. Commission Directive 2000/37/EC of 5 June 2000 amending Chapter VIa "Pharmacovigilance" of Council Directive 81/851/EEC on the approximation of the laws of the Member States relating to veterinary medicinal products. Official Journal of the European Communities. 2000;(L 139):25-27.
8. Commission Directive 2000/38/EC of 5 June 2000 amending Chapter Va (Pharmacovigilance) of Council Directive 75/319/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products. Official Journal of the European Communities. 2000;(L 139):28-30.
9. European Commission - Enterprise DG - Pharmaceuticals: Regulatory framework and Market authorisations. Pharmaceutical legislation: Notice to Applicants. The rules governing medicinal products in the European Union. Vol. 2; 2002. Available at: http://pharmacos.eudra.org/F2/eudralex/vol-2/home.htm, accessed July 10, 2002.
10. Commission Directive 91/356/EEC, of 13 June 1991, laying down the principles and guidelines of good manufacturing practice for medicinal products for human use. Official Journal of the European Communities. 1991;(L 193):30-33.
11. Committee for Proprietary Medicinal Products. Note for Guidance on quality, pre-clinical and clinical aspects of gene therapy medicinal products CPMP/BWP/3088/99. 2001. Available at: http://www.emea.eu.int/pdfs/human/bwp/308899en.pdf, accessed July 10, 2002.
12. The Journal of Gene Medicine. Gene Therapy Clinical Trials. John Wiley & Sons; 2001. Available at: http://www.wiley.co.uk/genetherapy/clinical/, accessed July 10, 2002.
13. European Agency for the Evaluation of Medicinal Products. Procedures for Orphan Medicinal Product Designation - General Principles: EMEA/14222/00. Available at: http://www.emea.eu.int/pdfs/human/comp/leaflet/661801En.pdf, accessed July 10, 2002.
14. Directive 2001/20/EC of the European Parliament and the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities. 2001;(L 121):34-44.